Emmaus Medical
  • CEO Letters
  • Overview
    • Mission
    • Leadership
      • Management Team
      • Board of Directors
    • Corporate Compliance
    • Corporate Governance
  • Products
    • Endari
  • Pipeline
    • Research Publications
    • Diverticulosis
    • Cell Sheet Engineering
  • News
    • Press Releases
    • Media Contacts
    • Media Kit
  • Investors
  • Career
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Pre-merger Emmaus Life Science SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Emmaus Life Sciences Presented Positive Real-World Data on the Efficacy of Endari® in Preventing Acute Complications from Sickle Cell Disease at the 62nd Annual Scientific Meeting of the British Society for Haematology

Apr 07, 2022 8:23am EDT

Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update

Mar 31, 2022 5:24pm EDT

Emmaus Life Sciences Announces Endari® To Be Added to the Florida Medicaid Preferred Drug List

Mar 29, 2022 8:23am EDT

Emmaus Life Sciences Receives U.A.E. Marketing Authorization for Endari®

Mar 23, 2022 8:23am EDT

Emmaus Life Sciences' Real World Data on Endari® Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for Haematology

Mar 04, 2022 8:23am EST

Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect Conference

Jan 04, 2022 8:23am EST

Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting

Dec 14, 2021 8:23am EST

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16th

Dec 09, 2021 8:00am EST

Emmaus Life Sciences' Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition

Dec 06, 2021 8:23am EST

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights

Nov 12, 2021 8:23am EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...17
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Emmaus Medical, Inc. Registered ® Emmaus Medical, Inc, Torrance, CA. All rights reserved.

    • Privacy
    • Terms of Use
    • Contact